Cargando…

Advances in the Treatment of Behcet’s Disease

PURPOSE OF REVIEW: To assess current management of Behcet’s disease (BD). Controversies on therapeutic approaches to different manifestations, whether conventional immunosuppressives (IS) or biologic agents, should be chosen, and options for refractory disease are discussed. RECENT FINDINGS: Glucoco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alibaz-Oner, Fatma, Direskeneli, Haner
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Vasculitis (C Dejaco and C Duftner, Section Editors)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136102/ https://www.ncbi.nlm.nih.gov/pubmed/34014377 http://dx.doi.org/10.1007/s11926-021-01011-z

Ejemplares similares

The Nasal Microbiome in ANCA-Associated Vasculitis: Picking the Nose for Clues on Disease Pathogenesis
por: Dekkema, G. J., et al.
Publicado: (2021)

Spectrum of Large and Medium Vessel Vasculitis in Adults: Primary Vasculitides, Arthritides, Connective Tissue, and Fibroinflammatory Diseases
por: Seitz, Luca, et al.
Publicado: (2022)

Spectrum of Large- and Medium-Vessel Vasculitis in Adults: Neoplastic, Infectious, Drug-Induced, Autoinflammatory, and Primary Immunodeficiency Diseases
por: Lötscher, Fabian, et al.
Publicado: (2022)

ANCA Status or Clinical Phenotype — What Counts More?
por: Windpessl, Martin, et al.
Publicado: (2021)

Patient Reported Outcomes in Large Vessel Vasculitides
por: Robson, Joanna, et al.
Publicado: (2021)

Blood Biomarkers for Monitoring and Prognosis of Large Vessel Vasculitides
por: Tombetti, Enrico, et al.
Publicado: (2021)

Localized Forms of Vasculitis
por: Martins-Martinho, Joana, et al.
Publicado: (2021)

Is There Still a Role of Plasma Exchange in the Current Management of ANCA-Associated Vasculitides?
por: Toyoda, Task, et al.
Publicado: (2022)

Biologic treatments in Behçet's disease
por: Alibaz-Öner, Fatma, et al.
Publicado: (2022)

Treatment of Giant Cell Arteritis and Takayasu Arteritis—Current and Future
por: Hellmich, B., et al.
Publicado: (2020)

Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis
por: Palmowski, Andriko, et al.
Publicado: (2020)

Imaging for Diagnosis, Monitoring, and Outcome Prediction of Large Vessel Vasculitides
por: Schäfer, Valentin Sebastian, et al.
Publicado: (2020)

Update on the Diagnosis of Behçet’s Disease
por: Alibaz-Oner, Fatma, et al.
Publicado: (2022)

Decreasing incidence and severity of Behçet’s disease: a changing trend in epidemiological spectrum possibly associated with oral health
por: MUMCU, Gonca, et al.
Publicado: (2020)

Development and preliminary validation of the Behçet’s syndrome Overall Damage Index (BODI)
por: Piga, Matteo, et al.
Publicado: (2020)

Impact of apremilast on quality of life in Behçet’s syndrome: analysis of the phase 3 RELIEF study
por: Hatemi, Gülen, et al.
Publicado: (2022)

Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing
por: Ortiz-Fernández, Lourdes, et al.
Publicado: (2023)

The assessment of contributing factors to oral ulcer presence in Behçet’s disease: Dietary and non-dietary factors
por: İris, Merve, et al.
Publicado: (2018)

40. Rivaroxaban for treatment of vascular BehÇet's disease
por: Musa, Reem, et al.
Publicado: (2018)

Avoidance of Harm From Treatment for ANCA-Associated Vasculitis
por: King, Catherine, et al.
Publicado: (2017)

Risk of tuberculosis is increased in Behçet’s disease compared to other rheumatological disorders after anti-TNFα treatments: a case series and review of the literature
por: GAZEL, Ümmügülsüm, et al.
Publicado: (2021)

90. Late diagnosis of Behçet’s patient with scleritis
por: Bashir, Yasmin, et al.
Publicado: (2018)

88. Fibromyalgia in BehÇet's disease: any role for helicobacter screen and eradication?
por: Bashir, Yasmin, et al.
Publicado: (2018)

Treatment failure in giant cell arteritis
por: Unizony, Sebastian H, et al.
Publicado: (2021)

Daratumumab for the treatment of refractory ANCA-associated vasculitis
por: Ostendorf, Lennard, et al.
Publicado: (2023)

Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis
por: Teixeira, Vítor, et al.
Publicado: (2019)

Treatment of polyarteritis nodosa with tocilizumab: a new therapeutic approach?
por: Saunier, Aurélie, et al.
Publicado: (2017)

Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task force
por: Sanchez-Alvarez, Catalina, et al.
Publicado: (2023)

Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis
por: Matza, Mark A, et al.
Publicado: (2023)

Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis
por: Brogan, Paul, et al.
Publicado: (2021)

Cardiovascular diseases and their associations with lipid parameters and endothelial dysfunction in giant cell arteritis
por: Jud, Philipp, et al.
Publicado: (2023)

Cardiovascular drug treatment, statins and biopsy-confirmed giant cell arteritis: a population-based case–control study
por: Turkiewicz, Aleksandra, et al.
Publicado: (2020)

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
por: Yates, Max, et al.
Publicado: (2017)

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1—treatment of granulomatosis with polyangiitis and microscopic polyangiitis
por: Schirmer, Jan Henrik, et al.
Publicado: (2023)

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
por: Smith, Rona M, et al.
Publicado: (2023)

87. Cardiac presentation of BehÇet's disease: the impact of HLA-B51 positivity in early diagnosis
por: Adamjee, Qainat R, et al.
Publicado: (2018)

Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids
por: Estupiñán-Moreno, Elkyn, et al.
Publicado: (2022)

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV
por: Sanchez-Alamo, Beatriz, et al.
Publicado: (2023)

Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease
por: Kubo, Satoshi, et al.
Publicado: (2022)

Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients
por: Prieto-González, Sergio, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_duoga5oki07jktbj15a56ou1kq